Novelna is a biotech company that has built a technology platform leveraging market-disrupting approaches in the early disease detection. Our core technology is proteomics-based, testing is minimally invasive (urine and/or serum-based) and products are optimized for high early-stage performance. What sets us apart from our competitors is our platform approach, the focus on early-stage detection, a clear commercial focus on competitiveness, a well-defined route to early regulatory approval, as well as our ability to produce new diagnostics products tailored to specific demands.